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ABSTRACT
Exertional rhabdomyolysis is characterised by muscle
breakdown associated with strenuous exercise or
normal exercise under extreme circumstances. Key
features are severe muscle pain and sudden transient
elevation of serum creatine kinase (CK) levels with or
without associated myoglobinuria. Mild cases may
remain unnoticed or undiagnosed. Exertional
rhabdomyolysis is well described among athletes and
military personnel, but may occur in anybody exposed
to unaccustomed exercise. In contrast, exertional
rhabdomyolysis may be the first manifestation of a
genetic muscle disease that lowers the exercise
threshold for developing muscle breakdown. Repeated
episodes of exertional rhabdomyolysis should raise the
suspicion of such an underlying disorder, in particular
in individuals in whom the severity of the
rhabdomyolysis episodes exceeds the expected
response to the exercise performed. The present review
aims to provide a practical guideline for the acute
management and postepisode counselling of patients
with exertional rhabdomyolysis, with a particular
emphasis on when to suspect an underlying genetic
disorder. The pathophysiology and its clinical features
are reviewed, emphasising four main stepwise
approaches: (1) the clinical significance of an acute
episode, (2) risks of renal impairment, (3) clinical
indicators of an underlying genetic disorders and (4)
when and how to recommence sport activity following
an acute episode of rhabdomyolysis. Genetic
backgrounds that appear to be associated with both
enhanced athletic performance and increased
rhabdomyolysis risk are briefly reviewed.
INTRODUCTION
Exertional rhabdomyolysis (ERM) is the
general term for muscle breakdown asso-
ciated with strenuous exercise and is well
described among athletes and military per-
sonnel. Although there is no universally
accepted deﬁnition, ERM is often deﬁned as
a clinical syndrome associated with severe
muscle pain, sudden elevation (and subse-
quent fall) of serum creatine kinase (CK)
levels with or without myoglobinuria.
Individuals experiencing ERM present to a
variety of physicians, in particular to general
practitioners and physicians working in
sports medicine, emergency and internal
medicine, neurology and the neuromuscular
ﬁeld, and for the military. As a result of the
diversity of medical personnel having to deal
with ERM, most physicians will have experi-
ence with some but not necessarily all
aspects of this important condition.
ERM results in the entry of skeletal muscle
contents, in particular CK and myoglobin,
into the systemic circulation. In most cases,
the condition has a mild course charac-
terised by postexertional myalgia with
mild-to-moderate CK increases, mild pigmen-
turia, and will often not even come to
medical attention. However, in a minority of
patients the clinical course can be severe,
resulting in marked hyperCKaemia, compart-
ment syndrome, acute renal injury, dissemi-
nated intravascular coagulation, cardiac
arrhythmias secondary to electrolyte imbal-
ances, and even cardiac arrest if left
untreated. The annual rhabdomyolysis
What are the new findings
▪ Exertional rhabdomyolysis (ERM) may be the
first manifestation of a genetic muscle disease
that lowers the exercise threshold for developing
muscle breakdown.
▪ Consider a genetic cause of the ERM in case of
recurrent episodes; high creatine kinase (CK)
levels (>50×upper limit of normal) or persisting
hyperCKaemia; absence of unaccustomed exer-
cise; absence of (recreational or medical) drugs;
or a positive family history of rhabdomyolysis or
other exertional symptoms.
▪ Type 1 ryanodine receptor (RYR1) mutations
have been recently recognised to account for a
substantial proportion of patients presenting with
ERM.
▪ Participants with a genetic predisposition to
ERM need specific guidance when they recom-
mence exercise and sporting activities.
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prevalence has been reported as 26 000 cases in the
USA, with 47% meeting the diagnostic criteria of ERM.1
In other studies, a lower percentage of ERM has been
suggested,2 a discrepancy which reﬂects differences in
the cohorts studied.
ERM most often represents a ‘physiological’ response
to extreme physical exercise or to normal exercise under
extreme circumstances. In contrast, ERM might also be
the ﬁrst manifestation of a genetic muscle disease, which
lowers the exercise threshold for developing muscle
breakdown. A genetic cause should always be considered
in individuals with repeated episodes of ERM and in
those in whom the severity of rhabdomyolysis exceeds
the expected response to the exercise performed.
The recognition of a patient with an underlying
genetic disorder is essential for acute management as
well as (and most importantly) for counselling after-
wards. First, in type 1 ryanodine receptor (RYR1)-related
cases of ERM,3 the speciﬁc RyR1 antagonist dantrolene
could be administered to limit further muscle break-
down and CK increases and more severe, potentially life-
threatening downstream medical complications. Patients
with RYR1-related ERM will have a higher recurrence
risk and will have to be speciﬁcally advised with regard
to subsequent sporting activities. The same patients are
also at increased risk of malignant hyperthermia suscep-
tibility (MHS), a pharmacogenetic response to volatile
anaesthetics and/or the depolarising muscle relaxant
succinylcholine, with important consequences for
affected individuals but possibly also for their relatives
carrying the same RYR1 variants. Furthermore, certain
genetic myopathies carrying an increased rhabdomyoly-
sis risk may also be associated with cardiac or other sys-
temic symptoms that will have to be screened for. Finally,
certain medications may be relatively contraindicated
and exercise advice should be individually adapted in
case of an underlying genetic cause.
The present review therefore aims to provide a prac-
tical guideline for the acute management and postepi-
sode counselling of patients with ERM. The vast majority
of the relevant literature until now has focused either on
the physiological circumstances of ERM (particularly in
publications with an emphasis on sports or military
medicine),4 5 on general causes of rhabdomyolysis,6 or
on genetic myopathies which may predispose to rhabdo-
myolysis (particularly in publications with an emphasis
on emergency medicine, genetics, neurology and neuro-
muscular medicine).7–9 As a result, physicians working
in sports or military and emergency medicine are well
updated on the symptoms and management of ERM,
but may ﬁnd it difﬁcult to decide when to consider an
underlying genetic disorder. On the other hand, a neur-
ologist may perform unnecessary muscle biopsies in
healthy individuals who have suffered from a single
episode of ERM after extreme unaccustomed exercise.
Therefore, a combined approach is necessary to recog-
nise individuals who are at risk for recurrent rhabdo-
myolysis and to advise patients with certain genetic
disorders on when and how to recommence exercise
and sporting activities.
We will ﬁrst discuss the pathophysiology of ERM and
its typical clinical features, and provide examples of
typical physiological ERM. Next, we will propose a struc-
tured approach to patients with ERM, based on the fol-
lowing four key questions: (1) is the ERM clinically
signiﬁcant, requiring hospital admission and intravenous
ﬂuids administration? (2) What is the risk of developing
acute renal failure (ARF)? (3) Is the ERM the (ﬁrst)
manifestation of a genetic disorder? And (4) when and
how to restart exercise and sporting activities? We expect
that such an approach will be of beneﬁt for a wide
range of physicians facing this severe and challenging
condition in different medical settings.
WHAT IS ERM?
Background
In muscle tissue, the process of neuronal signal transduc-
tion leading to muscle contraction is called excitation-
contraction coupling (ECC). During ECC, presynaptic
acetylcholine release induces postsynaptic depolarisation
of the sarcolemma, resulting in activation of the voltage-
gated L-type calcium channels (also known as dihydro-
pyridine receptors (DHPRs)). Unlike in cardiac muscle,
it is not this calcium inﬂux itself but rather the direct
interaction between DHPRs and RyR1s that causes the
opening of RyR1 Ca2+ channels, leading to a rapid
release of Ca2+ from the intracellular sarcoplasmic reticu-
lum (SR) stores. The increased myoplasmic Ca2+ (from
about 10-7 to 10-5 M) induces the effective interaction
between thick and thin ﬁlaments by binding to troponin
C, and this ultimately leads to muscle contraction. After
contraction, calcium needs to be restored. This happens
through active transport facilitated by the Ca2+ATPase,
an active process that on the molecular level takes 105
times longer than does RyR1-induced calcium release
but is compensated for by the large number of Ca2
+-ATPases on the surface of the SR membrane.10
Irrespective of its cause(s), the pathophysiological
events in rhabdomyolysis follow a common pathway.
Normally, ion pumps and channels in the sarcolemma
maintain a low intracellular Na+ and Ca2+ and a high
intracellular K+ concentration. Unaccustomed exercise
may cause direct injury to the sarcolemma (eg, in eccen-
tric exercise) and/or lead to failure of energy pro-
duction with subsequent pump dysfunction of
Na+/K+ATPase and Ca2+ATPase (eg, in prolonged train-
ing beyond the limit of fatigue). Both processes lead to
increased cellular permeability to sodium ions and, con-
sequently, increased intracellular calcium concentra-
tions, with concordant muscle contraction increasing
the energy deﬁcit. This increased intracellular calcium
concentration also enhances the activation of calcium-
dependent proteases and phospholipases, which contri-
butes to destruction of myoﬁbrillar, cytoskeletal and
membrane proteins. Subsequently, large quantities of
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intracellular electrolytes, metabolites (potassium, phos-
phate and urate) as well as intracellular proteins (aldo-
lase, myoglobin, CK, lactate dehydrogenase, aspartate
transaminase) leak into the circulation. The resulting
free calcium will only add to the contraction of the
already overactivated surrounding myocytes, resulting in
a vicious circle (ﬁgure 1).
Electrolyte disturbances occurring during exercise
(hypokalaemia by perspiration; hyponatraemia due to
polydipsia or medications) reinforce this process. Fluid
sequestration by damaged muscle leads to profound
intravascular volume depletion. This shift may over time
exceed 15 L and exacerbates the potential for ARF.
Potassium release from muscle cells during exercise nor-
mally mediates vasodilation and an appropriately
increased blood ﬂow to muscles. Decreased potassium
release due to profound hypokalaemia (serum potas-
sium <2.5 mEq/L) may promote the development of
rhabdomyolysis by decreasing blood ﬂow to muscles in
response to exertion, thus limiting availability of energy
sources. As rhabdomyolysis develops, potassium leaks
from myocytes into the bloodstream causing hyperkalae-
mia, which can result in fatal cardiac arrhythmias.
Hyponatraemia contributes to Na+/Ca2+-ATPase dysfunc-
tion, which leads to the activation of proteases and
lipases that are responsible for further cell lysis.
Furthermore, hyponatraemia causes failure of cell
volume regulation, leading to exertional cell lysis that
may stimulate vasopressin secretion.11 Thus, rhabdo-
myolysis may occur during the development of
hyponatraemia, or during its correction.12 Combined
with other cellular responses to exercise such as
increased oxidative stress13 and release of proinﬂamma-
tory cytokines,14 this will ultimately result in cell death
and intracellular components spilling into the surround-
ing tissue.
Myoglobin, the haemprotein that functions as an
oxygen carrier in skeletal muscle, is normally bound to
plasma globulins. In case of rhabdomyolysis, myoglobin
leaks from the myocyte and immediately peaks to levels
that may exceed the plasma protein-binding capacity. As
a result, myoglobin precipitates in the glomerular ﬁltrate
and obstructs renal tubules, an important factor in the
pathogenesis of ARF. Other factors contributing to ARF
include vasoconstriction, hypovolaemia and a direct
renal toxic effect of myoglobin.15
In our experience, rhabdomyolysis mainly occurs in
the muscles that are most frequently used. The type of
exercise performed also plays an important role in ERM.
In particular, eccentric training, for example, squats,
lunges, push-ups, plyometrics or running downhill,
carries a risk of causing ERM. Repetitive eccentric con-
tractions, a process where the muscle is lengthening
while trying to contract, cause excess tension in the
sarcomere, leading to membrane disruption and, subse-
quently, structural protein hydrolysis, myoﬁbril deform-
ation and permanent muscle injury. Eccentric exercise
has also been associated with core formation on muscle
biopsy, usually a histopathological hallmark of congenital
myopathies.16
Figure 1 Pathophysiology of rhabdomyolysis. The pathophysiological events in rhabdomyolysis follow a common pathway,
irrespective of its cause. CK, creatine kinase; SR, sarcoplasmic reticulum.
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Definition of ERM
What is generally agreed on are the following four key
features of rhabdomyolysis:
1. A CK elevation 12–36 hours after exercise, with a
maximum at 3–4 days, followed by normalisation
within several weeks of rest;
2. The CK increase is preceded by exercise, usually
beyond the limits of fatigue, also referred to as
‘unaccustomed physical exertion’ or ‘involuntary exertion’;
3. The CK increase is symptomatic with any of the follow-
ing features: myalgia (muscle soreness or tenderness;
in general, rhabdomyolysis is very painful), swelling
and/or weakness;
4. The presence of myoglobinaemia and/or myoglobinuria:
either by inspection (pigmenturia) or by laboratory
testing. Since myoglobin testing in blood or urine is
not widely available, many experts consider the com-
bination of the ﬁrst three features diagnostic for ERM.
CK elevation
The presence of elevated serum myoglobin was once
used routinely to diagnose rhabdomyolysis; however, this
parameter is not widely available for diagnostic testing
and unreliable because myoglobin is rapidly cleared
from the blood. Laboratory testing in urine (a positive
dipstick for blood with absence of red blood cells on
microscopic urinalysis serves as an indirect marker of
urinary myoglobin) offers a fast screening tool if serum
myoglobin testing is not readily available. Serum CK is
the most reliable diagnostic marker of rhabdomyolysis. It
usually peaks 24–36 hours after exertion and then
decreases back to baseline at a rate of about 40% per
day (ﬁgure 2).17
There is no consensus in the literature concerning the
exact level of CK increases required to fulﬁl the deﬁn-
ition of ERM, with suggested CK levels ranging from >5,
>10, >20 or even >50 times the upper limit of normal
(ULN).2 4 18–20 There is, however, some agreement that
the limit of a CK value of >5 times the ULN is very con-
servative, as it does not take into account documented
baseline differences as a function of gender, ethnicity
and training levels.18 21 22 These ULN levels vary consid-
erably: 217 and 414 IU/L in Caucasian women and
men, and 336 and 801 IU/L in African women and
men, respectively.23
Physiological exertional CK elevation
Several studies have investigated the occurrence of
rhabdomyolysis among healthy individuals exposed to
unaccustomed physical exertion, such as military recruits
during basic military training and athletes.20 24–27
Kenney et al studied a cohort of 499 healthy individuals
who participated in a 2-week basic military training,
including eccentric strength training. The cohort
included individuals of various ethnicities. The term
‘clinically symptomatic ERM’ was deﬁned more strin-
gently than the above: elevated serum CK, muscle weak-
ness and myoglobinaemia and/or myoglobinuria.
Hence, patients with myalgia in the absence of weakness
were not included. Based on this deﬁnition, no cases of
ERM were encountered. The mean and median CK
values were within normal limits (for sex and race) at
baseline, peaked with maximal elevation at day 7 and
returned to normal at day 14. Serum CK levels were
nearly universally elevated during training, but they were
also increased in nearly one-fourth of the participants at
baseline. At day 7, 27% of participants had CK levels >5
times the ULN, and 11% had levels >10 times the ULN,
with values ranging from 56 to 35 056 IU/L on day
7. There was no correlation whatsoever between CK
levels and the amount of exertion, environmental con-
ditions, or myalgia, or weakness. In fact, quite surpris-
ingly, and contrary to received opinion, CK elevations
were less pronounced during the hot, humid months.
One possible explanation was the less rigorous training
during the hot months.20 Hence, the authors proposed
that patients with serum CK levels <50 times the
ULN, no deﬁnite muscle swelling or weakness, no myo-
globinuria, and without laboratory evidence of ARF or
electrolyte imbalance have most likely expressed a
physiological response to exercise and should not be
classiﬁed as having ‘clinically signiﬁcant ERM’.20
Furthermore, the authors suggested that CK is only one
of the factors predicting morbidity and mortality in
ERM, which is in line with a recent risk stratiﬁcation
model.28
Unaccustomed physical exertion
A large number of cases and case series have been pub-
lished, reporting healthy individuals who were exposed
to levels of exercise they were not accustomed to. In
Figure 2 Rise and fall of myoglobin and creatine kinase
(CK) during the course of rhabdomyolysis. Myoglobin is the
first enzyme that increases, but returns to normal levels within
the first 24 hours after onset of symptoms. CK increases a few
hours later, reaches its peak value within the first 24 hours,
and remains at these levels for 3 days. Even though the
presence of myoglobin in serum is the key feature of
rhabdomyolysis, CK is considered to be a more useful marker
for the diagnosis and assessment of the severity of muscular
injury due to its delayed clearance from the plasma and the
wide availability for diagnostic testing. (Reprinted from
Giannoglou et al80 Copyright 2007, with permission from
Elsevier).
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particular, eccentric contractions increase the risk of
developing ERM. These exercises are well represented
in various extreme conditioning programmes (such as
‘CrossFit’, ‘Insanity’, ‘Gym Jones’). These programmes
typically involve high-volume and high-intensity physical
activities with short rest periods between movements and
use of multi-joint exercises and therefore require special
instructions for trainers and participants.29 In endurance
exercise such as marathon running, which does not
involve eccentric contractions, ERM seems to be less
common, and mostly in combination with other factors.
Most often, ERM affects physically untrained persons
who overexert themselves, particularly in hot weather.
Also, conditioned athletes may experience rhabdomyoly-
sis when they suddenly increase their training volume or
intensity or when they begin a new regimen requiring
intense eccentric muscle contractions.30 Several cases
have been reported during preseason training camps
taking place after prolonged periods of rest or reduced
exercise levels.30 31 In fact, ERM may occur to anyone
who performs physically ‘too much, too fast, too soon of
an exercise too novel’.31 The cluster of ERM affecting
the Division I Football team of Iowa university in 2011 is
probably the best known example of the latter.31 Two
days after a 3-week winter break, the team started an
intense training programme, consisting of strenuous
strength training including eccentric exercises. Within
1-week, 13 football players were hospitalised with ERM
(CK ranging from 96 987 to 331 044 IU/L). None devel-
oped compartment syndrome or problematic renal
failure; all were discharged as the symptoms subsided
during the next few days.31 This event led to the intro-
duction of an obligatory acclimatisation period during
the initial days of preseason camps.32
Several other studies conﬁrm the high CK increase
occurring in healthy individuals during unaccustomed
strenuous exercise.33–35 A study in healthy individuals
participating in lengthy marches (50 and 80 km) with
heavy backload also showed a huge increase of CK
during each march, reaching levels 40-fold to 80-fold
higher than the typical value for healthy sedentary parti-
cipants, reﬂecting ongoing muscle damage.34 Recently,
Oh et al presented clinical data from 30 previously
healthy patients admitted to a military hospital for ERM.
The exercise regimens included strength and resistance
training, CrossFit training and loaded marches. CK
levels ranged between 1565 and 410 755 IU/L, and in
nine participants CK was above 100 000 IU/L. All parti-
cipants recovered well and no complications were noted
at follow-up following discharge from the hospital.27 A
similar increase in rhabdomyolysis events occurred when
a swim coach added strenuous push-ups to the usual
training routine and when a gym teacher told 119 high
school students to do 120 push-ups in 5 min.36 Other
reports of triceps or biceps rhabdomyolysis have
included female lacrosse players, sailors aboard a ship, a
physician after a gym workout, a young man after a
rowing drill, and research volunteers in a laboratory
model of biceps overexertion.37–39 Apparently, strength
and conditioning coaches are generally well aware of
heat injury and dehydration, but not always of the risk of
ERM.31
Other external or acquired provoking factors
In addition to unaccustomed physical exercise, other
factors contributing to the risk of ERM include inad-
equate hydration, high ambient temperatures, supple-
ment use (ephedra, creatinine and herbal weight loss
supplements) or certain medications (statins, selective
serotonin reuptake inhibitors), illicit drug or alcohol
use, or recent viral illnesses. This is illustrated by the
report of a 31-year-old athlete and physiology professor
who experienced an episode of rhabdomyolysis after
resistance training, where high intrinsic motivation,
mental stress, use of supplements and dehydration were
identiﬁed as probably additive provoking factors.40
Along similar lines, the rare reported cases of rhabdo-
myolysis with ARF in marathon runners most likely
result from the combination of several factors, such as
heat stress, dehydration, non-steroidal anti-inﬂammatory
drug or other analgesic use, viral or bacterial infection,
and possibly latent myopathies.24
Most recently, obstacle races combining aerobic and
anaerobic activities performed at different environmen-
tal settings (eg, running and/or crawling on mud,
diving in freezing water and being exposed to electrical
discharges, which are commonly followed by alcohol
intake) such as Tough Mudder are becoming popular.41
This is associated with various risk factors for rhabdo-
myolysis such as extenuating exercise, dehydration and
exposure to heat, infectious disease, electrical pulses,
physical trauma and alcohol consumption.42
Furthermore, intense and enthusiastic coaching or
challenge by peers is the force that drives the already
highly motivated professional or recreational athletes
beyond their limit of exertion in many cases. This
includes sports teams, as well as inmates in prison and
soldiers.27 43–45
Symptoms of CK increase
In many patients, early, uncomplicated rhabdomyolysis is
subtle, with delayed-onset myalgia and localised oedema
being the only noted symptoms. Myalgia typically occurs
12–36 hours after the exercise. In a minority of patients,
generalised weakness and myoglobinuria are the pre-
senting symptoms. However, not all patients present with
this classic triad. Other symptoms include fatigue,
nausea, vomiting and fever. In severe cases, patients may
have delirium and oliguria. Muscle pain and weakness
can continue during and after recovery from rhabdo-
myolysis. In theory, an inﬂammatory myopathy may
occur with subsequent ﬁbrosis of muscle tissue.46 If the
patient is asymptomatic with a persistent and stable
raised CK, consider an underlying neuromuscular condi-
tion such as muscular dystrophy (table 1).
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Table 1 Genetic disorders with increased risk (or lowered threshold) of exertional rhabdomyolysis
Symptoms onset:
timely relation to
exercise
Type of exercise that
may trigger RM Diagnostic clue*
Muscle fuels and ATP production
Disorders of glycogen
metabolism
PYGM, PFKM, ENO3,
PGAM2, PGK1, PGM1,
PHKA1, PHKB
Few minutes Aerobic exercise
Anaerobic exercise
Strenuous exercise
Increased baseline CK level, vacuolar
myopathy with glycogen accumulation
(muscle biopsy), blunted increase in
lactate in forearm exercise test (except:
PHKA1, PHKB)
PYGM: second-wind phenomenon
PFKM: ‘out-of-wind phenomenon’,
polyglucosan bodies (muscle biopsy)
PGAM2: tubular aggregates (muscle
biopsy)
PGK1: central nervous system symptoms
PGM1: multisystem features
Haemolytic anaemia: PFKM, PGK1
Disorders of long-chain
fatty acid metabolism
ACADVL, CPT2, ETFA,
ETFB, ETFDH, MTP
Later onset
(Usually >45 min
to hours)
Prolonged aerobic exercise Symptoms are not triggered by isometric
muscle contraction
Abnormal fasting blood acylcarnitine
profile
Fasting and catabolic stress may trigger RM
ETFA, ETFB, ETFDH: metabolic acidosis
Peripheral neuropathy in MTP deficiency
MMs
COI (MTCO1), COII
(MTCO2), COIII (MTCO3),
FDX1 L, HADHA, HADHB,
ISCU, MTCYB, mtDNA
Unspecified Prolonged or repetitive
exercise
Strenuous exercise
Unspecified
Multisystem features
Abnormal muscle biopsy (ragged red
fibres, COX-negative fibres) Autosomal
recessive or maternal inheritance
iron-sulfur cluster assembly enzyme: iron
accumulation (muscle biopsy)
RM is exceptional in MMs and FAO
disorders should be excluded before
considering an MM.
Disorders of calcium homeostasis
Calcium-influx disorders
MHS
KDS
RYR1
Hours to a few
days
Unaccustomed exercise
Strenuous exercise
Exercise performed in
combination with different
triggers
Associated triggers (eg, hot weather),
muscle hypertrophy, heat intolerance
Caveolinopathy
CAV369
Minutes to a few
hours
Exercise (unspecified)
Moderate intensity of
endurance activity
Muscle rippling, PIRCs
Other structural myopathies
LGMD’s
Sarcoglycanopathies,
FKRP, DYSF70 71
Unspecified Prolonged intense exercise
Moderate physical activity
Weightlifting
Unspecified
Dystrophinopathies (DMD,
BMD or carrier state)57
DMD
Unspecified Unspecified Increased baseline CK level, gender
(DMD)
Other genetic conditions
Sickle cell trait During or
immediately after
exercise. A few
hours following
exercise.
Combination of intense
sustained exercise in
association with sickle cell
trait-related RM triggers
African descent
Risk of sudden death
Unspecified: symptoms may occur during or after exertion; little information about type of physical activilty is available in literature.
*The absence of a diagnostic clue does not exclude the diagnosis in some of the reported conditions.
BMD, Becker muscular dystrophy; CK, creatine kinase; COX, cytochrome c oxidase; DMD, Duchenne muscular dystrophy; KDS,
King-Denborough syndrome; LGMDs, limb-girdle muscular dystrophies; MHS, malignant hyperthermia susceptibility; MM, mitochondrial
myopathy; PIRCs, percussion-induced rapid muscle contractions; RM, rhabdomyolysis; RYR1, type 1 ryanodine receptor.
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Myoglobinuria and ARF
Myoglobinuria is deﬁned as the presence of myoglobin
in the urine, usually associated with rhabdomyolysis or
traumatic muscle injury. Myoglobin is the ﬁrst enzyme
that increases in plasma, but, because under physio-
logical circumstances it is readily ﬁltered by the glom-
erulus and rapidly cleared from the serum into the
urine, it normally returns to normal levels within the
ﬁrst 24 hours after symptom onset. However, when large
amounts of myoglobin enter the renal tubule lumen, it
interacts with the Tamm-Horsfall protein and precipi-
tates, a process enhanced in the presence of acidic
urine. Visible myoglobinuria (tea-coloured or cola-
coloured urine) occurs when urinary myoglobin exceeds
250 μg/mL (normal <5 ng/mL), corresponding to the
destruction of more than 100 g of muscle.47 Tubule
obstruction principally occurs at the level of the distal
tubule. In addition, reactive oxygen species generated by
damage to both muscle and kidney epithelial cells
promote the oxidation of ferrous oxide to ferric oxide,
thus generating a hydroxyl radical. Both the heme moi-
eties and the free iron-driven hydroxyl radicals may be
critical mediators of direct tubule toxicity, which mainly
occurs in the proximal tubule. A higher volume of urine
ﬂow and a higher urine alkalinity prevent myoglobin
from precipitating as readily as it would otherwise do.
Myoglobinuria causes little or no morbidity or mortal-
ity unless it is associated with the secondary complica-
tions of rhabdomyolysis, including hyperkalaemia,
hypocalcaemia and acute kidney injury. In adults, the
reported ARF incidence in patients with rhabdomyolysis
was reported to vary from 4.7% to 94% in a recent
review. This variation is likely to be at least partly due to
the differing deﬁnitions of rhabdomyolysis and ARF, and
to the differences in number and types of patients evalu-
ated.48 In the paediatric age group, although previous
small case series reported ARF rates of 40–50%, a large
retrospective review indicates that only about 5% of par-
ticipants with rhabdomyolysis develop acute kidney
injury.49 CK level is only one of the many determinants
of renal failure, including comorbidities, use of certain
medications, alcohol or illicit drugs and concomitant
electrolyte disturbances.28
Natural course of ERM
Among young, physically active patients, the incidence
of ERM is low, as is the risk of recurrence. Furthermore,
ERM is associated with lower complication rates com-
pared with other causes of rhabdomyolysis, probably
because participants do not have other associated dis-
eases or do not take potentially myotoxic treatments.
This was shown in a retrospective case series, including
population-based and cohort-based analyses in a cohort
of 177 patient with rhabdomyolysis at a US army medical
centre.25 There were 44 cases of ERM from a population
of 198 399 total military trainees over the study period,
or 22.2 cases per 100 000 per year. This was one-third of
all cases of rhabdomyolysis in this period; other causes
included trauma, use of toxins, infection and heat
illness. During the follow-up period (ranging from 20 to
60 months, with a mean of 31.2 months) with return to
prior levels of physical activity, there was one recurrence
of rhabdomyolysis (at 1-month, following exertion).25
Hence, long-term risk of recurrence is low. Other
reports, including that concerning the football team
cited above, also show that the prognosis of ERM
without systemic complications is very good.20 In
general, in the young, healthy population performing
sports at an intensity that may cause rhabdomyolysis,
complication rate is expected to be low.28
Genetic factors with increased risk for ERM
In addition, several genetic disorders increase the risk of
developing ERM. These include metabolic myopathies,
disorders of calcium homoeostasis and other structural
myopathies, and the sickle cell trait (table 1). RYR1
mutations have been recently recognised to account for
a substantial proportion of patients presenting with
ERM.3 Mutations in this gene are a common cause of
neuromuscular disease, ranging from various congenital
myopathies to the MHS trait without associated weak-
ness. Associated clinicopathological features in
RYR1-associated ERM may be subtle and require a high
degree of suspicion. Additional family studies are para-
mount in order to identify potentially MH-susceptible
relatives.3 50 51–53
Remarkably, some genetic disorders lower the thresh-
old for developing rhabdomyolysis and may also be asso-
ciated with greater athletic abilities. This is likely to be
the case for RYR1 mutations, in addition to what has
been reported regarding variants/polymorphisms in the
ACE and α-actinin-3 (ACTN3) genes.54–56 In other rare
situations, a combination of two genetic disorders may
alleviate exercise-related phenotypes such as the coexist-
ence of α-thalassaemia and sickle cell trait, lowering risk
for exercise collapse associated with the sickle cell trait
(ECAST).57
Emerging evidence suggests that speciﬁc polymorphic
variants in a number of genes also increase the suscepti-
bility of developing ERM (table 2). For example, the
ACTN3 XX genotype is associated with changes in
muscle function as per the structural, metabolic and sig-
nalling role played by ACTN3, which might increase the
susceptibility to muscle damage, especially due to eccen-
tric exercise.58 59 Single nucleotide polymorphisms of
the CK muscle-speciﬁc (CK-MM) isoform and myosin light
chain kinase 2 (MYLK2) genes were also found in signiﬁ-
cantly higher frequencies in patients who presented with
severe episodes of ERM.60 However, in the reported
study, the authors did not specify the other genetic
causes of rhabdomyolysis that had been investigated as
part of the diagnostic workup. Moreover, the patients
and control groups were not exposed to the same
amount of exercise, and possible provoking factors were
not considered. Further studies will be required to deter-
mine the molecular mechanism(s) whereby these
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Table 2 Genes with polymorphic variants previously reported in association with increased susceptibility to ERM or exercise
heat tolerance
Gene
Exercise-related
increased CK
Exercise-related
muscle damage
Other features/study
sample
Type of
exercise that
triggered
muscle
symptoms
Differential
diagnosis for
well-known
genetic causes
of RM
ACE
II>ID>DD72
Yes NK Healthy young
volunteers; CK
assessed pre, 3, 24, 48,
72, 96, 120 and
168 hours postexercise
Strenuous
eccentric
contractions
NK
ACTN3
R577X60
NK Previous history
of severe ERM
Control group and
affected patients did not
perform the same
amount of exercise
NK A detailed list
containing the
investigated
disorders in people
with ERM was not
provided.
ACTN3
R577X73
Yes NK Cortisol, testosterone,
IL-6, α-actin and CK
assessed pre,
immediately after, 2 and
4 hours postexercise
Professional athletes
Eccentric NK
CCL2
rs391787874
Yes (women) Attenuated
strength recovery
(men)
Blood samples from a
previous clinical trial on
topical non-steroidal
anti-inflammatory
CK assessed pre, 4, 7
and 10 days
postexercise
Strenuous
eccentric
contractions
NK
CCR2
rs3918358
rs179986574
Likely Slower recovery
(women—
rs3918358) and
soreness
(rs1799865)
Blood samples from a
previous clinical trial on
topical non-steroidal
anti-inflammatory
CK assessed pre, 4, 7
and 10 days
postexercise
Strenuous
eccentric
contractions
NK
MYLK
49 T75
Yes No Blood samples from a
previous clinical trial on
topical non-steroidal
anti-inflammatory
CK assessed pre, 4, 7
and 10 days
postexercise
Higher baseline strength
Strenuous
eccentric
contractions
NK
MYLK
C37885A75
Yes Postexercise
strength loss
Blood samples from a
previous clinical trial on
topical non-steroidal
anti-inflammatory
CK assessed pre, 4, 7
and 10 days
postexercise
Strenuous
eccentric
contractions
NK
MYLK
C37885A60
NK Previous history
of severe ERM
Control group and
affected patients did not
perform the same
amount of exercise
NK A detailed list
containing the
investigated
disorders in people
with ERM was not
provided.
Continued
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variants confer a real risk. The use of new diagnostic
techniques such as next generation sequencing and
whole exome sequencing in large samples of patients
with recurrent rhabdomyolysis in conjunction with func-
tional studies may be more appropriate to identify
genuine ‘rhabdomyolysis susceptibility genotypes’.
CLINICAL APPROACH
The clinical approach of patients with ERM consists of 4
steps: (1) Is the ERM clinically signiﬁcant, requiring
hospital admission and intravenous ﬂuid administration?
(2) What is the risk of developing ARF? (3) Is the ERM
the (ﬁrst) manifestation of a genetic disorder? And (4)
when and how to restart exercise and sporting activities?
Step 1: is the ERM clinically significant?
The ﬁrst step when encountering a patient with a high
CK after strenuous exercise is to determine whether the
rhabdomyolysis is clinically signiﬁcant, requiring hospital
admission and intravenous ﬂuid administration. There
Table 2 Continued
Gene
Exercise-related
increased CK
Exercise-related
muscle damage
Other features/study
sample
Type of
exercise that
triggered
muscle
symptoms
Differential
diagnosis for
well-known
genetic causes
of RM
CK-MM Ncol60 NK Previous history
of severe ERM
Control group and
affected patients did not
perform the same
amount of exercise
NK A detailed list
containing the
investigated
disorders in people
with ERM was not
provided.
CK-MM Ncol76 Yes NK Healthy volunteers (86%
Caucasians); CK
assessed immediately,
48 and 72 hours
postexercise
Short duration
(6 min),
moderate
intensity, mostly
anaerobic
exercise
NK
IGF-II
rs3213221
rs68077
Yes Strength loss and
soreness
Blood samples from a
previous clinical trial on
topical non-steroidal
anti-inflammatory
CK assessed pre, 4, 7
and 10 days
postexercise
Women: no association
Strenuous
eccentric
contractions
NK
IGF2AS
A1364C77
Yes Strength loss and
soreness
Blood samples from a
previous clinical trial on
topical non-steroidal
anti-inflammatory
CK assessed pre, 4, 7
and 10 days
postexercise
Women: no association
Strenuous
eccentric
contractions
NK
IL-6
G174C
CC>GC>GG78
Yes NK Healthy young
volunteers; CK
assessed pre, 3, 24, 48,
72, 96, 120 and
168 hours postexercise
Strenuous
eccentric
contractions
NK
TNFA G308A78 Yes (GG) NK Healthy young
volunteers; CK
assessed pre, 3, 24, 48,
72, 96, 120 and
168 hours postexercise
Strenuous
eccentric
contractions
NK
RYR152 79 Inconsistent Inconsistent Susceptibility to MH;
muscle weakness (CCD)
CCD, central core disease; CK, creatine kinase; ERM, exertional rhabdomyolysis; IL, interleukin; NK, not known (not assessed or not
described); RM, rhabdomyolysis; RYR1, type 1 ryanodine receptor.
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are no compelling randomised controlled trials offering
concrete management guidelines for this question or
other aspects of rhabdomyolysis treatment. However, the
study of Kenney et al reporting many cases of physio-
logical ERM offers a practical guideline for this ﬁrst step
(which includes laboratory investigations for renal func-
tion and electrolytes) by demonstrating that patients
with a CK<50 times the ULN, with absence of muscle
weakness or swelling, no myoglobinuria and normal
renal function and electrolytes are very likely to have a
physiological ERM episode.20 For clarity and to be on
the safe side, we propose the CK level of 10 000 IU/L
(∼50 times the ULN of white women) as a cut-off point
for assessment at the emergency room (table 3).20 61
The goals of inpatient or outpatient treatment are to
avoid renal injury, prevent further muscle injury and
avoid complications of electrolyte disturbances (box 1).
Step 2: what is the risk of developing ARF?
The second step takes place during evaluation in the
emergency room, and concerns the assessment of the
risk of ARF and mortality, according to a recently devel-
oped algorithm, which shows that the risk of ARF
increases with a CK>40 000 IU/L.28 Other risk factors
Table 3 Selection of patients who require hospital admission and intravenous fluid administration
Physiological ERM Clinically significant ERM
Clinical features Only myalgia Also muscle weakness and/or swelling and/or
altered consciousness
Vital signs Normal Abnormal and/or body temperature >40°C
(heat stroke)
Exercise Clearly unaccustomed Accustomed/unaccustomed
CK (U/L) <10 000 ≥10 000
Myoglobinuria/myoglobinaemia Absent Present
Acute renal failure Absent Absent or present
Electrolyte abnormalities Absent Absent or present
Acid base status Normal Abnormal
Other factors possibly provoking
rhabdomyolysis
Absent Absent or present
History ▸ No prior episodes of ERM
▸ No other indicators of NMD
▸ No renal, cardiac or pulmonary
medical comorbidity
▸ Prior episodes of ERM
▸ Other indicators of NMD
▸ Renal, cardiac or comorbidity
Outpatient follow-up if all normal Referral to the ER in case of any of these
factors
CK, creatine kinase; ERM, exertional rhabdomyolysis.
Box 1 Management of exertional rhabdomyolysis (ERM)
Outpatient follow-up of patients with physiological ERM18
▸ Rest for 72 hours and encourage oral hydration
▸ Sleep 8 hours consecutively, nightly
▸ Remain in thermally controlled environment if ERM occurred in association with heat injury
▸ Refer to ERM in case temperature exceeds 40°C
▸ Follow-up in 72 hours for repeat creatine kinase (CK) and blood urea:
– CK<5×upper limit of normal (ULN) and normal blood urea: no further studies
– Return every 72 hours and repeat until CK<5×ULN and normal blood urea
– CK≥5×ULN or abnormal blood urea for >2 weeks: refer for expert consultation
– CK≥50×ULN (10 000 U/L): refer to ERM again
▸ Refrain from sports
▸ Elimination of medications, drugs and toxins that are considered to cause rhabdomyolysis
Clinical management of patients with clinically significant rhabdomyolysis4 48 62
▸ Hyperhydration: Intravenous fluids should be initiated as soon as possible, preferably within the first 6 hours after muscle injury, at a rate
that maintains a urine output in adults of ≥300 mL/hours for at least the first 24 hours
▸ Admit at an ICU and consider peritoneal dialysis or haemodialysis in patients with little or no urine output despite hyperhydration, pro-
found acidosis or severe hyperkalaemia
▸ Mannitol should be administered only to maintain urine output of 300 mL/h or more despite adequate fluid administration
▸ Sodium bicarbonate should be administered only if necessary to correct systemic acidosis
▸ Elimination of medications, drugs and toxins that are considered to cause rhabdomyolysis
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are age >50 years, female sex, initial creatinine >1.4 mg/
dL and additional metabolic changes (hypocalcaemia,
hyperphosphataemia, decreased bicarbonate) (table 4).
The ability to identify these patient early in the course
of a rhabdomyolysis episode is useful for early institution
of aggressive prophylactic measures, admission to the
ward or intensive care unit, and communication with
patients and families about prognosis. Scharmann has
summarised the available evidence concerning therapies
to prevent kidney injury in rhabdomyolysis.48
In general, serial physical and laboratory examinations
are necessary to manage patients with ERM appropri-
ately.4 In the acute phase, treatment should be aimed at
preserving renal function and restoring metabolic
derangements. Early and adequate volume replacement
with isotonic sodium chloride solution 0.9% (no
potassium-containing or lactate-containing solutions)
may directly prevent renal injury by aiding clearance of
toxic substances and increasing renal perfusion pressure.
Volume expansion increases renal blood ﬂow and, con-
sequently, glomerular ﬁltration and urination. A
common goal of treatment is to achieve a urine output
of 300 mL/hour. This may require infusion of intraven-
ous ﬂuids by 1–2 L/hour until urine output is stable.
Intravenous ﬂuid should preferably be continued until
serum CK activity in plasma has declined to 1000 IU/L
Table 4 Assessment of risk of acute renal failure and other complications
Diagnostic tests used in the evaluation of rhabdomyolysis
General examination Assess the level of consciousnessCheck for signs of:
▸ Dehydration
▸ Systemic infection
▸ Trauma
▸ Compartment syndrome
▸ Exertion heat stroke
History Check medication use62
▸ Antipsychotics (haloperidol, fluphenazine, perphenazine, chlorpromazine)
▸ Cyclic antidepressants and selective serotonin reuptake inhibitors
▸ Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, cerivastatin)
▸ Fibric acid derivatives (bezafibrate, clofibrate, fenofibrate, gemfibrozil)
▸ Quinine
▸ Salicylates
▸ Theophylline
▸ Antibiotics (fluoroquinolones, pyrazinamide, trimethoprim/sulphonamide, amphotericin B,
itraconazole, levofloxacin)
▸ Zidovudine
▸ Antihistamines
▸ Aminocaproic acid
▸ Phenylpropanolamine
▸ Sodium valproate
▸ Anaesthesia with volatile anaesthetics a/o succinylcholine
▸ Benzodiazepines
▸ Corticosteroids
Vital signs Check for signs of hypovolaemia and shock
Serum CK Elevated as a result of muscular damage: >5, >10, >20 or even >50 times the ULN
Serum potassium Elevated levels indicate muscular damage and potassium leakage from cells
Hyperkalaemia increases the patient’s risk for dysrhythmias
Serum sodium Check for exercise-associated hyponatraemia
Renal function Blood urea nitrogen and serum creatinine—assess renal function and hydration status.
An elevated ratio may suggest dehydration, and an elevated creatinine level may suggest renal
dysfunction.
Myoglobinuria Presence of urine myoglobin suggests muscular damage
Absence of urine myoglobin does not preclude exertional rhabdomyolysis
(optional; CK levels are normally used to guide management)
Acid base status Check for metabolic acidosis
Coagulation tests Abnormal results may indicate disseminated intravascular coagulation
ECG Check for dysrhythmias if the patient has hyperkalaemia or other electrolyte abnormalities
Cardiac isoenzymes Rule out cardiac infarction
Toxicology screening Check blood and urine for (illicit) drug abuse
Risk assessment Use the ‘Risk prediction score for kidney failure or mortality in rhabdomyolysis’ by McMahon
et al.28
CK, creatine kinase; ULN, upper limit of normal.
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or below. In patients with little or no urine output
despite aggressive hydration, profound acidosis or severe
hyperkalaemia, consider peritoneal dialysis or haemodi-
alysis and consult a nephrologist. Aggressive hydration
may not be appropriate in patients with other comorbid-
ities such as heart failure. Furthermore, if kidney injury
is already established, overly aggressive hydration in a
patient with already established renal failure may lead to
volume overload and pulmonary oedema.
Mannitol leads to an increase in blood ﬂow and glom-
erular ﬁltration, which reduces the obstruction by myo-
globin casts. It must only be given after volume
replacement and must be avoided in patients with oli-
guria. It is not routinely recommended, but may be
administered if the target urine output cannot be
achieved by other means. Loop diuretics have also been
investigated, but published data are too limited to
support recommending them routinely. Although not
proven by randomised control trials, some experts rec-
ommend the addition of bicarbonate. Alkalisation of the
urine (target pH 6.5) promotes myoglobulin washout
and corrects the metabolic acidosis and hyperkalemia. A
recent systematic review has shown that sodium bicar-
bonate should only be administered to patients with sys-
temic acidosis.48
Monitoring for and treating rhabdomyolysis-related
electrolyte abnormalities is an important part of man-
aging patients with ERM. Hyperkalaemia, hypocalcae-
mia, hyperphosphataemia and hyperuricaemia are
common in patients with rhabdomyolysis, and should be
treated with standard therapy. Although hypocalcaemia
is common in early rhabdomyolysis, hypercalcaemia can
occur later. Calcium supplementation should only be
prescribed for patients with symptomatic hypocalcaemia
or severe hyperkalaemia. More research is needed to
determine whether allopurinol may be useful for pre-
venting ERM and acute renal damage.13
Compartment syndrome requires surgical consultation.
If the compartment pressure measured by an intramus-
cular needle exceeds 50 mm Hg, or if pressure persists
between 30 and 50 mm Hg for longer than 6 hours,
decompressive fasciotomy must be considered.63
Haemorrhagic complications in patients with dissemi-
nated intravascular coagulation (DIC) and rhabdomyoly-
sis require careful management. Drugs and toxins
should be eliminated (eg, haemodialysis/antidotes) if
possible. Anaesthetic precautions (such as avoidance of
depolarising muscle relaxants and volatile anaesthetics)
should be taken in patients with an ongoing rhabdo-
myolysis. Anaesthetic precautions are also suggested for
undiagnosed patients with strong evidence of an under-
lying RYR1-related rhabdomyolysis episode and of course
for MHS patients and their relatives.
Step 3: is the ERM the (first) manifestation of a genetic
disorder?
Several studies and reviews have focused on the under-
lying genetic causes of (exertional) rhabdomyolysis.6–9 64
However, the key questions are: in which patients should
an underlying genetic disorder be considered, and
hence which patients should be referred for a more spe-
cialist neuromuscular consultation after the recovery
from the initial rhabdomyolysis episode?
In general, ‘benign ERM’ is the ﬁnal conclusion if no
underlying genetic cause is detected after several diag-
nostic studies.6 However, in order to prevent unneces-
sary invasive diagnostic procedures, it would be better to
start with an assessment of the risk of an underlying dis-
order. Landau et al8 proposed an algorithm for both
acute management and follow-up. This includes selec-
tion criteria for patients to be referred for further evalu-
ation for and underlying genetic (neuromuscular)
disease. The criteria proposed are in line with those in
other reviews: ‘persistent hyperCKemia or weakness
4 weeks after the event’; ‘a (family) history of
exercise-induced, fasting-induced or fever-induced
rhabdomyolysis or malignant hyperthermia’, and the
‘presence of exertional muscle cramps or exercise
intolerance’.
We suggest a few additional clinical indicators, based
on the risk for recurrence assessment proposed by
O’Connor et al,18 the high-risk criteria brought up by
Szczepanik and our own experience.65 The ﬁrst clinical
indicator is ‘rhabdomyolysis in case of accustomed exer-
cise’: if the rhabdomyolysis occurs in a trained athlete
who has worked out at a level of intensity that he is used
to (in the absence of other provoking factors), the exer-
cise is not ‘unaccustomed’. The absence of team-related
cases of ERM also points to the exercise that was not
unaccustomed to the level of physical ﬁtness. In these
cases, there is a greater likelihood of ﬁnding an under-
lying genetic cause. A genetic cause is also more likely
when different members of the same family suffer a
rhabdomyolysis event simultaneously, for example,
during the same intermittent viral illness or during the
same sports event,3 66 or when onset is in childhood.
Finally, an underlying genetic condition should be sus-
pected in patients in whom exercise is the only under-
lying cause, or in whom other exogenous causes (drugs,
medication (including anaesthesia), infection) seem
insufﬁcient to explain the severity of the rhabdomyolysis
episode.2 40
In order to improve the recognition of patients with
an increased risk, we propose the use of the acronym
‘RHABDO’: screening for a genetic cause should be con-
sidered if any of the criteria below are present (table 5).
We refer to table 1 and recent detailed reviews for an
overview of genetic disorders to be considered.6–9
Step 4: when and how to recommence exercise and
sporting activities?
No evidence-based guidelines concerning return to
physical activity after ERM are currently available. The
natural course of ERM in cases without suspicion of a
genetic disorder suggests that return to sports is safe.25
During follow-up (ranging from 20 to 60 months, with a
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mean of 31.2 months), there was only one recurrence of
rhabdomyolysis (at 1-month, following exertion) in this
cohort, yielding a recurrence risk of 0.08% per person
per year.25 Several expert opinion guidelines advise
refraining from sports for at least 4 weeks, until the CK
has normalised, and then begin light activities (box 2).
O’Connor et al18 suggests three phases of return to
physical exercise for athletes who are not at risk: phase
1: onset to normalisation of CK to <5 times the ULN;
phase 2: start of light activities; phase 3: gradually return
to regular sporting activities and physical training
(guideline evolved from the Rhabdomyolysis Working
Group at the Consortium for Health and Military
Performance (CHAMP)).
CONCLUSION
We have presented an overview of clinical and diagnostic
aspects of ERM, in a stepwise approach. At each step, it
is important to distinguish normal physiological reac-
tions from ERM as the ﬁrst manifestation of a genetic
disorder. It is essential for physicians working at the
‘physiological’ end (sports medicine/military medicine)
and those working at the clinical end of the medical
spectrum (emergency medicine, internal medicine,
Box 2 Guideline to restart exercise and sporting activities
Advice to restart sport >4 weeks of the event and patient is asymptomatic
Patients without suspicion of a genetic disorder
▸ Begin light but no strenuous physical activities
▸ Follow-up with physician in 1-week
▸ In case of clinical symptoms (muscle weakness, swelling or myalgia) remain in start schedule and return at 1-week intervals
▸ Only if no clinical symptoms (muscle weakness, swelling or myalgia) return, gradually increase the intensity and duration
▸ Avoid unaccustomed exercise, especially eccentric training
▸ Follow-up with care provider as needed
Patients with (suspicion of ) a genetic disorder in general
Additional advices:
▸ Search help of a physical therapist/sports medicine specialist/rehabilitation specialist with expertise of training in inherited myopathies
▸ Wear an SOS necklace
▸ Very gradual return to a less-intense training schedule
▸ Strictly avoid the combination of strenuous exercise with other risk factors for rhabdomyolysis (drugs, medication, supplements, viral
infection)
▸ Strictly avoid unaccustomed exercise, especially eccentric training
▸ Prevent dehydration during exercise
▸ Do limit training intensity in hot and humid environment
▸ Report to physician in case of exertional myalgia and perform creatine kinase check-up
Additional advice in case of metabolic myopathies:
▸ Prevent fasting
▸ Avoid sugar intake just before exercising (Tarui disease)
▸ Getting into the second wind phenomenon routinely (McArdle disease)
▸ Avoid exercising if catabolic stress; eg, infection (fatty acid oxidation disorders)
Additional advice in case of type 1 ryanodine receptor (RYR1)-related exertional rhabdomyolysis:
▸ Prevent the combination of extreme heat exposure and strenuous exercise
▸ Do not use caffeine or other supplements
▸ Limit alcohol consumption in periods of intense sport activities
Additional advice in case of sickle cell trait:
▸ Patient should be asymptomatic
▸ Prevent dehydration before, during and after exercise
▸ Do not use caffeine, other supplements or drugs prior to exercise without medical advice
▸ Avoid exercising in the presence of other triggers for sickle cell trait-related rhabdomyolysis (hot and humid weather, high altitude, con-
comitant infection, etc)67
▸ Assess previous history of exercise collapse associated with sickle cell trait (ECAST) for further advice68
Table 5 Selection of patients for screening of a genetic
disorder
Consider a genetic cause of the exertional
rhabdomyolysis in case of ‘RHABDO’
R Recurrent episodes of exertional rhabdomyolysis
H HyperCKaemia persists 8 weeks after the event
A Accustomed physical exercise
B Blood CK>50×ULN (>10 000 ULN in female
Caucasian patients)
D Drugs/medication/supplements and other exogenous
and endogenous factors cannot sufficiently explain the
rhabdomyolysis severity
O Other family members affected/Other exertional
symptoms (cramps, myalgia)
CK, creatine kinase; ULN, upper limit of normal.
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neurology) to consider that ERM can happen to anyone
who is exposed to unaccustomed exercise. The thresh-
old, however, is much lower in patients with an under-
lying genetic disorder. In addition, several other
exogenous and endogenous factors also lower this
threshold. The most important question is whether the
level and type of exercise in combination with other
exogenous and endogenous factors is sufﬁcient to
explain the rhabdomyolysis episode. If not, screening for
an underlying genetic (neuromuscular) disorder needs
to be performed.
Future research should focus on deﬁning speciﬁc,
evidence-based training and exercise advice for patients
with various myopathies, in order to prevent recurrent
episodes of rhabdomyolysis while enabling patients to
optimise their physical condition or even improve their
strength. New treatments to reduce the risk of ERM
should be prospectively tested in various cohorts of
patients with genetic risk factors for rhabdomyolysis.13
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